Equities

Klotho Neuroscience Inc

KLTO:NMQ

Klotho Neuroscience Inc

Actions
FinancialsOpen End and Miscellaneous Investment Vehicles
  • Price (USD)0.82
  • Today's Change-0.07 / -7.87%
  • Shares traded528.00
  • 1 Year change-92.31%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Klotho Neuroscience, Inc., formerly ANEW Medical, Inc., is a specialty pharmaceutical company. The Company specializes in the development of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. The Company focuses on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer's disease (AD), dementia symptoms and neuromuscular diseases. It has exclusive worldwide rights to develop and commercialize product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or s-KL. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease. Its lead gene therapy product candidates are AMI-101 (AAV9-CMV-sKL) (Alzheimer's disease), and AMI-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig's disease.

  • Revenue in USD (TTM)0.00
  • Net income in USD-744.61k
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bimini Capital Management Inc17.44m-5.33m9.91m9.00--1.23--0.5682-0.5315-0.53151.740.80120.1563--48.901,937,262.00-4.78-1.94-13.50-5.4960.9264.24-30.60-32.95----0.9318--301.1320.5479.91------
Green Planet Bioengineering Co Ltd0.00-38.63k10.00m-----------0.0019-0.00190.00-0.0223---------------------------127.77---------46.54------
Neon Bloom Inc741.11k-1.36m10.59m8.00------14.29-8.33-8.334.49-11.161.0913.9671.7192,638.75-200.77-------67.49---183.47--0.0542-11.93-----50.99---561.49------
Global Acquisitions Corp0.00-66.56k10.66m7.00---------0.0118-0.01180.00-0.11370.00-------60,509.09-5,181.61-------------------------21.68------
Chase Packaging Corp0.00190.58k11.63m--61.2435.85----0.00310.00310.000.00520.00------51.60-105.6151.87-106.28------------0.00-------621.11------
BKF Capital Group Inc11.30m-15.00k11.69m3.00--1.61177.191.04-0.0257-0.025719.3712.441.022.6812.25--0.19775.050.27716.0831.13--0.194714.65---0.14870.00--253.62---79.84------
Santech Holdings Ltd - ADR261.34m-142.21m12.00m2.91k------0.0459-5.10-5.109.02--1.13--4.7789,961.14-62.1210.85-156.5220.5394.41---55.178.81----0.000.007.7112.68-44.9425.28-6.06--
Klotho Neuroscience Inc0.00-744.61k12.41m-----------0.0255-0.02550.00-0.0990.00-------2.46---2.56--------------1.66------9.14------
Sos Ltd - ADR92.42m-3.65m12.49m181.001.300.0202--0.13510.48710.48710.516831.330.19691.9857.03510,585.60-1.37-19.41-1.54-23.1715.35---6.95-44.85----0.00---64.464.1498.41------
IMD Companies Inc439.50k-330.55k13.14m3.00------29.90-0.0053-0.00530.0049-0.00210.430331.325.58146,500.00-32.36-41.61-43.47-58.1633.5249.68-75.21-89.491.05--1.48--26.65---47.11------
CaliberCos Inc72.10m-14.17m14.17m99.00------0.1966-0.6588-0.65883.36-0.21520.2751--1.58728,282.80-10.26---19.32-------37.29-----5.570.4767--8.32---724.50------
Renn Fund Inc309.88k1.10m14.45m0.0013.140.9195--46.640.15680.15680.04422.240.02--12.97--7.101.927.211.9374.8550.50354.89173.97----0.00--27.9235.0379.10------
Xsovt Brands Inc-230.00-2.27m14.75m0.00---------0.1416-0.1416-0.00002-0.0753-0.0013-------1,249.08--------100.00---37,918.24---10.04-----66.13---1.90------
Safeguard Scientifics Inc0.00-9.83m15.09m33.00--0.7508-----0.6063-0.60630.001.200.00-------32.475.63-34.696.10-----------0.91930.00------31.09------
Data as of Sep 19 2024. Currency figures normalised to Klotho Neuroscience Inc's reporting currency: US Dollar USD

Institutional shareholders

3.27%Per cent of shares held by top holders
HolderShares% Held
Meteora Capital LLCas of 30 Jun 2024391.80k2.27%
MM Asset Management, Inc.as of 30 Jun 202480.00k0.46%
RiverNorth Capital Management LLCas of 30 Jun 202420.02k0.12%
D. E. Shaw & Co. LPas of 30 Jun 202420.00k0.12%
Koch Industries, Inc. (Investment Management)as of 30 Jun 202420.00k0.12%
Citadel Securities LLCas of 30 Jun 202411.03k0.06%
Gabelli & Company Investment Advisers, Inc.as of 30 Jun 202410.00k0.06%
UBS Securities LLCas of 30 Jun 20249.60k0.06%
BofA Securities, Inc.as of 30 Jun 2024189.000.00%
Barclays Capital, Inc.as of 30 Jun 2024110.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.